Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Ely

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Nature|June 18, 2025
Editorial Expression of Concern: Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirusOrnella Flore, Shahin Rafii, Scott Ely, et al.
Blood|January 13, 2004
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSuzanne Trudel, Scott Ely, Yildiz Farooqi, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2021
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesPeter M Szabo, Saumya Pant, Scott Ely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
CD74 is expressed by multiple myeloma and is a promising target for therapyJack D Burton, Scott Ely, Praveen K Reddy, et al.
Cancer|September 24, 2010
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaRuben Niesvizky, Scott Ely, Tomer Mark, et al.
Leukemia & Lymphoma|January 12, 2019
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myelomaPeter A Forsberg, Andrew Hammes, Diana Abbott, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Cell Cycle (Georgetown, Tex.)|May 17, 2013
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1David Chiron, Peter Martin, Maurizio Di Liberto, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2004
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1Xiangao Huang, Maurizio Di Liberto, Adam F Cunningham, et al.
Cancer Research|December 17, 2005
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myelomaScott Ely, Maurizio Di Liberto, Ruben Niesvizky, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Nature|June 18, 2025
Editorial Expression of Concern: Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirusOrnella Flore, Shahin Rafii, Scott Ely, et al.
Blood|January 13, 2004
Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSuzanne Trudel, Scott Ely, Yildiz Farooqi, et al.
The Journal of Molecular Diagnostics : JMD|July 1, 2021
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor TypesPeter M Szabo, Saumya Pant, Scott Ely, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
CD74 is expressed by multiple myeloma and is a promising target for therapyJack D Burton, Scott Ely, Praveen K Reddy, et al.
Cancer|September 24, 2010
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myelomaRuben Niesvizky, Scott Ely, Tomer Mark, et al.
Leukemia & Lymphoma|January 12, 2019
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myelomaPeter A Forsberg, Andrew Hammes, Diana Abbott, et al.
Leukemia & Lymphoma|March 11, 2015
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomasPeter Martin, Richard R Furman, Sarah Rutherford, et al.
Cell Cycle (Georgetown, Tex.)|May 17, 2013
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1David Chiron, Peter Martin, Maurizio Di Liberto, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 14, 2004
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1Xiangao Huang, Maurizio Di Liberto, Adam F Cunningham, et al.
Cancer Research|December 17, 2005
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myelomaScott Ely, Maurizio Di Liberto, Ruben Niesvizky, et al.
Pageof 5